Posted by Michael Wonder on 11 Jun 2020
LEO Pharma announces European Medicines Agency acceptance of marketing authorisation application for tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis
11 June 2020 - LEO Pharma today announced that the European Medicines Agency validated the marketing authorization application for tralokinumab, an investigational product for the treatment of adult patients with moderate-to-severe atopic dermatitis.
The acceptance of this application marks the beginning of the formal review procedure for this potential new treatment by the EMA’s Committee for Medicinal Products for Human Use.
